2-Chlorodeoxyadenosine: An Active Agent in the Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphomas are disfiguring malignant lymphoproliferative disorders for which standard therapy has been principally palliative. 2-Chlorodeoxyadenosine (2-CdA), a new purine analogue resistant to degradation by adenosine deaminase that has substantial activity against lymphoid neoplasm...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1992-08, Vol.80 (3), p.587-592
Main Authors: Saven, Alan, Carrera, Carlos J., Carson, Dennis A., Beutler, Ernest, Piro, Lawrence D.
Format: Article
Language:English
Subjects:
2-Chloroadenosine - adverse effects
2-Chloroadenosine - analogs & derivatives
2-Chloroadenosine - therapeutic use
Aged
Aged, 80 and over
Antigens, CD - analysis
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chemotherapy
Cladribine
Deoxyadenosines - adverse effects
Deoxyadenosines - therapeutic use
Female
Follow-Up Studies
Humans
Lymphoma, T-Cell, Cutaneous - drug therapy
Lymphoma, T-Cell, Cutaneous - immunology
Lymphoma, T-Cell, Cutaneous - pathology
Male
Medical sciences
Middle Aged
Neoplasm Staging
Pharmacology. Drug treatments
Skin Neoplasms - drug therapy
Skin Neoplasms - immunology
Skin Neoplasms - pathology
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous T-cell lymphomas are disfiguring malignant lymphoproliferative disorders for which standard therapy has been principally palliative. 2-Chlorodeoxyadenosine (2-CdA), a new purine analogue resistant to degradation by adenosine deaminase that has substantial activity against lymphoid neoplasms, was administered to 16 patients with cutaneous involvement by T-cell lymphoma. All patients had failed topical treatment modalities and/or systemic therapies. Fifteen patients were evaluable; one patient was not evaluable due to incomplete therapy and follow-up. The overall response rate was 47%. Three of 15 patients (20%) achieved complete responses and four of 15 patients (27%) achieved partial responses. The median duration of response was 5 months. One patient remains in unmaintained complete remission at 52+ months. Therapy was well tolerated. Myelosuppression was the principal toxicity encountered, occurring in 8 of 15 (53%) patients. 2-CdA is an effective new agent for the treatment of cutaneous T-cell lymphoma and warrants further study both as a single agent and in combination regimens.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V80.3.587.587